Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Assets (2017 - 2025)

Serina Therapeutics' Non-Current Assets history spans 9 years, with the latest figure at $916000.0 for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 116.89% year-over-year to $916000.0; the TTM value through Sep 2025 reached -$11.8 million, down 3136.54%, while the annual FY2024 figure was $1.0 million, 22.31% down from the prior year.
  • Non-Current Assets for Q3 2025 was $916000.0 at Serina Therapeutics, up from -$8.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $10.9 million in Q2 2023 and bottomed at -$8.0 million in Q2 2025.
  • The 5-year median for Non-Current Assets is $936000.0 (2021), against an average of $932833.3.
  • The largest annual shift saw Non-Current Assets soared 1179.51% in 2023 before it plummeted 546.18% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $920000.0 in 2021, then fell by 14.35% to $788000.0 in 2022, then soared by 71.19% to $1.3 million in 2023, then fell by 22.31% to $1.0 million in 2024, then fell by 12.6% to $916000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Non-Current Assets are $916000.0 (Q3 2025), -$8.0 million (Q2 2025), and -$5.8 million (Q1 2025).